Get the Stockscreener App
9.34
0.43%
-0.04
Biocryst Pharmaceuticals Inc stock is traded at $9.34, with a volume of 1.85M.
It is down -0.43% in the last 24 hours and down -6.60% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$9.38
Open:
$9.41
24h Volume:
1.85M
Relative Volume:
0.38
Market Cap:
$2.37B
Revenue:
$885.72M
Net Income/Loss:
$-457.98M
P/E Ratio:
-5.2575
EPS:
-1.7765
Net Cash Flow:
$293.05M
1W Performance:
+0.54%
1M Performance:
-6.60%
6M Performance:
+37.56%
1Y Performance:
+9.24%
1-Day Range:
$9.295
$9.485
1-Week Range:
$9.11
$9.69
52-Week Range:
$6.00
$11.22
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.34 | 2.37B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Resumed | Evercore ISI | Outperform |
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Biocryst Pharmaceuticals Inc. (BCRX) Fundamental & Financial Data - Stocktwits
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BCRX Q2'26 Earnings: revenue estimate is 183.28M USD - TradingView
(BCRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals - simplywall.st
BioCryst schedules a look at second-quarter results for Aug. 5 - Stock Titan
BioCryst to Report Second Quarter 2026 Financial Results on August 5 - The Manila Times
Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story? - Sahm
BioCryst Pharmaceuticals (BCRX) Proxy filing Summary - Quartr
BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary - Quartr
Citizens reiterates BioCryst stock rating on Orladeyo revenue outlook By Investing.com - Investing.com Nigeria
BioCryst stock trades steadily as Orladeyo revenue supports rare disease focus - ad-hoc-news.de
Citizens reiterates BioCryst stock rating on Orladeyo revenue outlook - Investing.com
BioCryst Appoints David W. Jenkins as Chief Scientific Officer - Sahm
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $15 - Moomoo
BioCryst Pharmaceuticals Names David W. Jenkins Chief Scientific Officer to Lead External Innovation Strategy - Quiver Quantitative
BioCryst names David Jenkins as chief scientific officer By Investing.com - Investing.com Canada
BioCryst’s New Science Chief Brings Over 20 Years in Biopharma - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet - Zacks Investment Research
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits
BCRX Reinstated by JP Morgan -- Price Target Announced at $12.00 - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reshapes R And D As Fair Value Narrative Stays In Focus - Sahm
BioCryst (BCRX) Coverage Resumed by JPMorgan with Neutral Rating - GuruFocus
JPMorgan resumes BioCryst Pharma stock coverage with neutral rating - Investing.com
JPMorgan resumes BioCryst Pharma stock coverage with neutral rating By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Cantor Global Healthcare Conference 2025 Summary - Quartr
Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model? - Sahm
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility - Yahoo Finance
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal? - Yahoo Finance
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Icatibant Acetate Market Growth Driven by HAE Diagnosis Expansion and Self-Administration Trends Through 2035News and Statistics - IndexBox
Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD By Investing.com - Investing.com South Africa
Biocryst Pharmaceuticals stock hits 52-week high at 10.94 USD - Investing.com
RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating - Moomoo
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14 - Moomoo
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):